Pseudorabies

14,000,000 Leading Edge Experts on the ideXlab platform

Scan Science and Technology

Contact Leading Edge Experts & Companies

Scan Science and Technology

Contact Leading Edge Experts & Companies

The Experts below are selected from a list of 12741 Experts worldwide ranked by ideXlab platform

Kegong Tian - One of the best experts on this subject based on the ideXlab platform.

  • Detection of Pseudorabies Virus Antibodies in Human Encephalitis Cases
    Biomedical and environmental sciences : BES, 2020
    Co-Authors: Ling Yan Chen, Jun Hua Deng, Huan Yu Wang, Kegong Tian
    Abstract:

    Pseudorabies virus (PRV), a veterinary pathogen that infects domestic animals as well as wild animals such as wild boar and feral swine, was recently reported to infect human and led to endophthalmitis and encephalitis. A retrospective seroepidemiologic survey was conducted using 1,335 serum samples collected from patients with encephalitis and ELISA positive rates were 12.16%, 14.25%, and 6.52% in 2012, 2013, and 2017, respectively. The virus neutralizing antibody titers of positive samples correlated well with ELISA results. The Pseudorabies virus antibody positive rate of patients with encephalitis were higher than that of healthy people in 2017. The above results suggest that some undefined human encephalitis cases may be caused by PRV infection.

  • Generating Recombinant Pseudorabies Virus for Use as a Vaccine Platform.
    Methods in molecular biology (Clifton N.J.), 2017
    Co-Authors: Feifei Tan, Kegong Tian
    Abstract:

    Pseudorabies virus (PRV) is a promising vaccine vector due to its distinctive features including many nonessential replication regions and a broad host range. Foreign genes of other viruses have been successfully inserted into and expressed in PRV and these recombinant viruses are very likely to induce humoral and/or cellular responses in immunized animals. This chapter offers an overview of methods for generating recombinant Pseudorabies virus for use as a vaccine vector.

Tong Guang-zhi - One of the best experts on this subject based on the ideXlab platform.

  • Minimum dose of protection of recombinant Pseudorabies virus (rPRV-GP5) against Pseudorabies in sheep
    Journal of Guangxi Agricultural and Biological Science, 2006
    Co-Authors: Tong Guang-zhi
    Abstract:

    To test the minimum dose of protection of the recombinant Pseudorabies virus(PRV) expressing porcine reproductive and respiratory syndrome virus(PRRSV) GP5(rPRV-GP5) developed earlier against Pseudorabies,twenty-four 5~6-month-old sheep were randomly divided into six groups,each group of 4 sheep,groups of 1~5 were immunized intramuscularly 5×10~4.0 TCID_50、5×10~3.0 TCID_50、5×10~2.0 TCID_50、5×10~1.0 TCID_50respectively and 5 TCID_50,respectively and group 6 was served as control.Fifteen days after immunization,all sheep of groups 1~6 were injected by intramuscular with 10~3 LD_50 of the highly virulent PRV S strain of porcine origin.The results showed that vaccinated sheep in groups 1~3 were complete protected from PRV,two sheep in group 4 also were protected,all sheep in group 5 and 6 died,the minimum dose of protection of rPRV-GP5 against Pseudorabies in sheep is 100 TCID_50.

  • The Progress of Pseudorabies virus Gene-Deleted and Vector Vaccine
    Progress in Veterinary Medicine, 2005
    Co-Authors: Zhou Guo-hui, Qiu Huaji, Tian Zhi-jun, Tong Guang-zhi
    Abstract:

    Pseudorabies is caused by Pseudorabies virus(PRV),which is a member of family herpesviridae and is the agent of acute infectious disease in many domestic and wild animals.Infection may result in signs ranging from clinically inapparent latent carrier states to fatal respiratory tract or neurologic disease syndromes.The virus is responsible for major economic loss in pig industries worldwide.Vaccination is one of the most effective prophylactic measure to prevent the disease. In this assay,research progress on PRV gene-deleted and virus vector vaccine used extensively today was discussed.

  • Safety and efficacy of recombinant Pseudorabies virus (rPRV-GP5) against Pseudorabies in sheep
    Chinese Journal of Preventive Veterinary Medicine, 2004
    Co-Authors: Tong Guang-zhi
    Abstract:

    To test the safety and efficacy of the recombinant Pseudorabies virus (PRV) expressing porcine reproductive and respiratory syndrome virus (PRRSV) GP5 (rPRV-GP5) developed earlier against Pseudorabies,Ten 5～ 6-month-old sheep were randomly divided into three groups,one group of 4 sheep (efficacy group) were immunized intramuscularly 10~(6.0) PFU,one group of 3 sheep (safety group) were immunized intramuscularly 10~(6.0) PFU,and the third group of 3 sheep were served as control group.Fourteen days post-immunization,animals in efficacy and control groups were challenged by intramuscular inoculation with 10~3 LD50 of the highly virulent PRV S strain of porcine origin.The results showed that vaccinated sheep were protected from lethal challenge of PRV,and rPRV-GP5 represents a candidate vaccine against porcine Pseudorabies.

Ziguo Yuan - One of the best experts on this subject based on the ideXlab platform.

  • a recombinant Pseudorabies virus expressing rabies virus glycoprotein safety and immunogenicity in dogs
    Vaccine, 2008
    Co-Authors: Ziguo Yuan, Shoufeng Zhang, Fei Zhang, Anthony R Fooks, Qianxue Li, Rongliang Hu
    Abstract:

    Summary Several recombinant vaccines expressing the rabies virus glycoprotein have been developed, particularly for the oral vaccination of wildlife. While these vaccines induce protective immunity in some animal species such as foxes, they are less effective in others. Pseudorabies virus (PRV) has been licensed for use as a live vaccine in pigs and possesses an excellent safety and efficacy record. We have used it to construct a recombinant virus, rPRV/eGFP/rgp, expressing the rabies virus glycoprotein. This recombinant virus has been shown to be safe for dogs by oral and intramuscular routes of inoculation and was demonstrated to induce immune responses against both Pseudorabies and rabies in dogs after a single oral dose of 2 × 10 7.0  plaque forming units (PFU). Neutralizing antibody titers against rabies reached >0.5 IU/ml and 1:64–1:128 against Pseudorabies by 5 weeks post-vaccination in all dogs, indicating that the Pseudorabies virus vector infected dogs and replicated in vivo , and that the rabies virus glycoprotein had been expressed and an effective immune response elicited. Antibody titers were maintained for over 6 months. This suggests that Pseudorabies virus could be an effective live vector for recombinant rabies oral vaccination.

Wenhong Zhang - One of the best experts on this subject based on the ideXlab platform.

Huanchun Chen - One of the best experts on this subject based on the ideXlab platform.

  • Magnetic beads-based electrochemical immunosensor for detection of Pseudorabies virus antibody in swine serum.
    Talanta, 2011
    Co-Authors: Rui Zhou, Kaihong Zhao, Huanchun Chen
    Abstract:

    A novel magnetic electrochemical immunosensor has been developed for the detection of Pseudorabies virus antibody in swine serum. The magnetic glass carbon electrode was fabricated to manipulate magnetic beads for the direct sensing applications. Magnetic beads were employed as the platforms for the immobilization and immunoreaction process, and gold nanoparticles were chosen as electroactive labels for the electrochemical detection. The parameters concerning the assay strategy were carefully investigated. Under the optimal conditions, the linear response range of Pseudorabies virus antibody dilution ratio (standard positive serum) was 1:250 to 1:1000 with a detection limit of 1:1000. Finally, this developed immunoassay method was successfully applied in the detection of Pseudorabies virus antibody in swine serum, and had a good diagnostic accordance in comparison with ELISA.

Related terms

Pseudorabies - 15 days free trial to Access Experts & Abstracts